Selected Publications

  • Tian F, Forouzannia F, Feng Z, Biondi M, Mendlowitz A, Feld J, Sander B, Wong W.W.L. (2024). Feasibility of hepatitis C elimination by screening and treatment alone in high-income countries. Hepatology, in press [Link]

  • Forouzannia F, Hamadeh A, Passos-Castilho AM, Erman A, Yu A, Feng Z, Janjua N, Sander B, Greenaway C, Wong W.W.L. (2024) Impact of new direct direct-acting antiviral therapy on the prevalence and undiagnosed proportion of chronic hepatitis C infection in Canada, Liver International, in press [Link]

  • Hirniak S, Edginton A, Iorio A, Alasabbagh W, Hajducek D, Wong W.W.L. (2024). Health utilities in adults with hemophilia A: A retrospective cohort study. Hemophilia, in press [Link]

  • Masucci L, Tian F, Tully S, Feng Z, McFarlane T, Chan KKW, Wong W.W.L. (2024). CAR T-cell Therapy for Diffuse Large B-cell Lymphoma in Canada: A Cost–Utility Analysis. Medical Decision Making, v44:3:296–306 [Link] 

  • Anyiwe K, Erman A, Hassan M, Feld J, Pullenayegum E, Wong W.W.L., Sander B.  (2024) Characterizing the effectiveness of social determinants of health-focused hepatitis B interventions: A systematic review. Lancet Infectious Disease, in press [Link]
 
  • Wong W.W.L., Haines A, Wong J, Hamadeh A, Krahn M (2023). A  province-by-province cost-effectiveness analysis and budget impact analysis of one-time birth cohort screening of hepatitis C virus (HCV) infection in Canada. Scientific Report, v13:13484 [Link]
 
  • Wong W.W.L., Lee L, Walker S, Lee C, Patel T, Hillier L, Costa A, Sinha SK (2023). Cost-effectiveness analysis of Multispecialty Interprofessional Team (MINT) Memory Clinics versus usual dementia care in Ontario, Canada. BMJ Open, v13:e064882 [Link]
 
  • Chayab L., Konstantelos N., Leighl N., Tadrous M., Wong W.W.L. (2023). Systematic review of cost effectiveness analyses of Anaplastic Lymphoma Kinase (ALK) inhibitors in Non-Small Cell Lung Cancer (NSCLC) patients. PharmacoEconomics, v41:945-980 [Link]
 
  • Wong WWL, Wong J, Bremner B, Saeed Y, Mason K, Phoon A, Martel-Laferrière V, Bruneau J, Feld J, Feng Z, Baguley E, Lee S, Powis J, Krahn M. (2023) Impact of direct-acting antiviral treatment on health utility in patients with chronic hepatitis C in hospital and community settings. Liver International, v43:4:805-818 [Link]
 
  • Kim J, Alsbbagh W, Wong WWL (2023). Cost-Effectiveness of Implementing a Universal Birth Hepatitis B Vaccination Program in Ontario. PharmacoEconomics, v41:945-980 [Link]

  • Saeed Y, Mason K, Mitsakakis N, Feld J, Bremner K, Phoon A, Fried A, Wong J, Powis J, Krahn M, Wong WWL. Socioeconomic Marginalization is Associated with Lower Health State Utility Values in Chronic Hepatitis C Patients. (2023) Canadian Liver Journal, v6:1:24-38 [Link]
 
  • Tian F, Feld J, Feng Z, Sander B, Wong W.W.L. (2022) Feasibility of hepatitis B elimination in high-income countries with ongoing immigration. Journal of Hepatology, v77,4:947-956 [Link]

  • Koo V, Tian F, Wong WWL (2022).  Cost-effectiveness analysis of hepatitis C virus (HCV) point-of-care assay for HCV screening. Liver International, v42,4:787-795 [Link]
 
  • Wong WWL, Wong J, Bremner K, Saeed Y, Mason K, Phoon A, Feng Z, Feld J, Mitsakakis N, Powis J, Krahn M (2022). Time costs and out-of-pocket costs in chronic hepatitis C patients in a publicly funded health system. Value in Health, v25,2:247-256 [Link]
 
  • Hamadeh A, Feng Z, Niergarth J, Wong WWL (2021).  Estimation of the COVID-19 prevalence and undiagnosed proportion in Canadian provinces. JMIR Public Health and Surveillance, v7,9:e26409 [Link]
 
  • Tran C-P, Kim J, Feld J, Wong WWL (2021). Cost-effectiveness of obeticholic acid for the treatment of non-alcoholic steatohepatitis: An early economic evaluation. Canadian Liver Journal, v4,4:360-369 [Link]
 
  • Wong WWL, Haines A,  Bremner KE, Yao Z, Calzavara A, Mitsakakis N, Kwong J, Sander B, Thein H, Krahn M (2021). Health care costs associated with chronic hepatitis C virus infection in Ontario, Canada: a retrospective cohort study, CMAJ Open, v9,1:E167-E174 [Link]
 
  • Ellis K, Grindrod K, Tully S, McFarlane T, Chan KKW, Wong WWL (2021). Understanding the feasibility of implementing CAR T-cell therapies from a Canadian perspective. Healthcare Policy, v16,3:89-105 [Link]
 
  • Chan J, Kim J, Barrett BK, Hamadeh A, Feld J, Wong WWL (2021). Cost-Effectiveness Analysis of Sofosbuvir and Velpatasvir in Chronic Hepatitis C Patients with Decompensated Cirrhosis. Journal of Viral Hepatitis, v28,2:260-267 [Link]
 
  • Hamadeh A, Haines A, Feng Z, Thein H, Janjua NZ, Krahn M, Wong WWL  (2020).  Prevalence estimates of chronic hepatitis C in British Columbia and Ontario using health administrative data. Journal of Viral Hepatitis, v27,12:1419-1429 [Link]
 
  • Lipton J, Zargar M, Warner E, Greenblatt E, Lee E, Chan KK, Wong WWL (2020). Cost effectiveness of in vitro fertilization and preimplantation genetic testing to prevent transmission of BRCA1/2 mutations. Human Reproduction, v35,2:434-445 [Link]
 
  • Kim J, McFarlane T, Tully S, Wong WWL (2020) Lenvatinib versus sorafenib as first-line treatment of unresectable hepatocellular carcinoma: a cost-utility analysis. The Oncologist, v25,3:e512-e519 [Link]
 
  • Tian F, Houle S, Alsabbagh W, Wong WWL (2020). Cost-effectiveness of Tenofovir Alafenamide for treatment of chronic hepatitis B in Canada. PharmacoEconomics, v38,2:181-192 [Link]
 
  • Saeed YA, Phoon A, Bielecki JM, Mitsakakis N, Bremner K, Abrahamyan L, Pechlivanoglou P, Feld J, Krahn M, and Wong WWL (2020) A Systematic Review and Meta-analysis of Health Utilities in Chronic Hepatitis C Patients, Value in Health, v23,1:127-137 [Link]
 
  • Erman A, Wong WWL,  Feld J; Grootendorst P,  Krahn M. (2020) The health impact of delaying direct-acting antiviral treatment for chronic hepatitis C: a decision-analytic approach. Liver International, v40:51-59 [Link]
 
  • Wong WWL, Pechlivanoglou P, Wong J, Bielecki J, Haines A, Erman A, Saeed Y, Phoon A, Tadrous M, Younis M, Rayad N, Rac V, Janssen HLA, Krahn M. (2019) Antiviral treatment for chronic hepatitis B: Systematic review and network meta-analysis of randomized controlled trials, Systematic Reviews,v8:207 [Link]

  • Wong WWL, Zargar M, Berry S, Ko Y, Riesco-Martinez MC, and Chan KK (2019). Cost-effectiveness analysis of selective first line use of biologics for wild-type RAS unresectable metastatic colorectal cancer based on primary tumor location.  Current Oncology, v26,5:e597-e609 [Link]
 
  • Hamadeh A, Feng Z, Krahn M, Wong WWL (2019).  A Model-based framework for chronic hepatitis C prevalence estimation. PLoS One, v14,11:e0225366. [Link]
 
  • Tully S, Feng Z, Grindrod K, McFarlane T, Chan KKW, Wong WWL (2019) Impact of increasing wait-times on overall mortality of Chimeric Antigen Receptor T-cell therapy in large B-cell lymphoma: A discrete event simulation model. JCO Clinical Cancer Informatics, v3:1-9. doi: 10.1200/CCI.19.00086.[Link]
 
  • Erman A, Krahn M, Hansen T, Bielecki J, Feld J; Wong WWL, Grootendorst P, Thein HH. (2019) Estimation of Fibrosis Progression Rates for Chronic Hepatitis C: A Systematic Review and Meta-Analysis Update, BMJ Open, v9:e027491 [Link]
 
  • Pullagura GR, Waite NM, Houle S, Violette R, Wong WWL (2019). Cost-utility analysis of offering a remunerated community-pharmacist consultation service on influenza vaccination for seniors in Ontario, Canada. Journal of the American Pharmacists Association, v59,4:489-497 [Link]

  • Farhang Zangneh H, Wong WWL, Sander B, Bell C, Mumtaz K, Kowgier M, van der Meer A, Cleary S, Janssen H, Chan KK, Feld J (2019) Cost-Effectiveness Analysis of Annual Versus Biannual Ultrasound Surveillance for Hepatocellular Carcinoma in Patients with Hepatitis C Related Cirrhosis after Sustained Viral Response. Clinical Gastroenterology and Hepatology, v17,9:1840-1849 [Link]

  • van Tilborg M, Almarzooqi S, Wong WWL,Maan R, Vermehren J, Maasoumy B, Mazzulli T, Bolotin S, Garber G, Guerra F, Flud CR, Kowgier M, Janssen HL, de Knegt RJ, Pawlotsky J-M, Cloherty GA, Duarte-Rojo A, Sarrazin C, Wedemeyer S, Feld JJ (2018) HCV core antigen as an alternative to HCV-RNA testing in the era of direct-acting antivirals. The Lancet Gastroenterology & Hepatology, v3, 12: p856-864. [Link]
    ​
  • Wong WWL, Haines A, Zangneh H, Shah H. (2018) Can we afford not to screen and treat HCV infection in Canada. Canadian Liver Journal, v2,51:65 [Link]
 
  • Zargar M, McFarlane T, Chan KK, Wong WWL. (2018). Cost-Effectiveness of Nivolumab in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma in Canada. The Oncologist, v23,2:225-233 [Link]
 
  • Saluja R, Arciero VS, Cheng S, McDonald E, Wong WWL, Cheung MC, Chan K.K. (2018). Examining trends in cost and clinical benefit of novel anti-cancer drugs over time. Journal of Oncology Practice, v14, 5: e280-e294 [Link]
 
  • Bolotin S, Feld J, Garber G, Wong WWL, Guerra F, Mazzulli T. Population-based estimate of hepatitis C virus prevalence in Ontario, Canada. (2018)  PLOS ONE, v13, 1:e0191184. [Link]
 
  • Erman A, Sathya A, Nam A, Bielecki J, Feld J; Thein HH, Wong WWL, Grootendorst P,  Krahn M.  Estimating Chronic Hepatitis C Prognosis Using Transient Elastography-Based Liver Stiffness: A Systematic Review and Meta-Analysis. (2018) Journal of Viral Hepatitis, v25, 5:502-513 [Link]
   
  • Wong WWL, Erman A, Feld J, Krahn M. (2017).  Model-Based Projection of Health and Economic Effects of Screening Hepatitis C: Informing on Screening Recommendations in Canada. CMAJ Open, v5, 3:E662-E672 [Link]
 
  • Wong W.W.L., Lee K., Singh S., Wells G., Feld J., Krahn M. (2017) Drug therapies for Chronic hepatitis C infection: a cost-effectiveness analysis. CMAJ Open, v5, 1:E97-E108. [Link]
 
  • Wong W.W.L., Feng Z.Z, Thein H-H. (2016). A parallel sliding region algorithm to make agent-based modeling possible for large-scale simulation: modelling hepatitis C epidemics in Canada.  IEEE Journal of Biomedical and Health Informatics, v20,6:1538-1544. [Link]
 
  • Sander B., Wong W.W.L., Ormanidhi O., Atkin, K., Murphy, J., Krahn M., and Deeks S. L. (2016). The Cost-Effectiveness of Integrated Cervical Cancer Prevention Strategies in the Ontario Setting – Can We Do Better? Vaccine, v34, 16:1936–1944. [Link]
 
  • Riesco-Martinez M.C., Berry S., Ko Y., Mittmann N., Giotis A., Lien K., Wong W.W.L., and Chan K.K. (2016).  Cost effectiveness analysis of the use of EGFR inhibitors for wild type (WT) KRAS unresectable metastatic Colorectal Cancer (mCRC).  Journal of Oncology Practice, v12, 6: e710-e723. [Link]
 
  • Wong W.W.L., Hicks L.K., Tu H-A, Pritchard K.I., Krahn M.D., Feld, J., Chan K.K.. (2015). Hepatitis B Virus Screening before Adjuvant Chemotherapy in Patients with Early Stage Breast Cancer: A Cost-Effectiveness Analysis.  Breast Cancer Research and Treatment, v151 3:639-652. [Link]

  • Lee E.K, Wong W.W.L., Trudeau M.E., Chan K.K. (2015). Cost-Effectiveness of Prophylactic Granulocyte Colony-Stimulating Factor for Febrile Neutropenia in Breast Cancer Patients Receiving FEC-D.  Breast Cancer Research and Treatment, v150 1:169-180. [Link]

  • Wong W.W.L., Tu H-A., Feld, J., Wong, T., Krahn M. (2015). Cost-Effectiveness of Screening Hepatitis C in Canada. Canadian Medical Association Journal (CMAJ), v187, 3:E110. [Link]
 
  • Wong W. W. L., Griesman J., Feng Z. (2014) Imputing Genotypes Using Regularized Generalized Linear Regression Models, Statistical Applications in Genetics and Molecular Biology, v13, 5:519-529. [Link]
 
  • Wijeysundera H., Wong W. W. L., Bennell M., Fremes S. E., Radhakrishnan S., Peterson M., Ko, D.T. (2014). Impact of increasing wait times on the effectiveness of transcatheter aortic-valve replacement (TAVR) in high-risk and inoperable patients with severe aortic disease: a discrete event simulation model. The Canadian Journal of Cardiology, v30, 10:1162-1169. [Link]
 
  • Wong W. W. L., Woo, G., Heathcote J.E., Krahn M. (2013). Disease Burden of Chronic Hepatitis B among Immigrants in Canada.  Canadian Journal of Gastroenterology, v27, 3:137-147. [Link]
 
  • Oliverira C., Nguyen V.H., Wijeysundera H., Wong W. W. L., Woo, G., Grootendorst P., Liu P., Krahn M. (2013). Estimating the payoffs from cardiovascular disease research in Canada: an economic analysis.  CMAJ Open, v1, 2:E83:E90. [Link]
 
  • Nguyen V.H., Oliverira C., Wijeysundera H., Wong, W. W. L., Woo, G., Grootendorst P., Liu P., Krahn M. (2013). Canada's Contribution to Global Research in Cardiovascular Diseases. The Canadian Journal of Cardiology, v29, 6:742-746. [Link]
 
  • Oliverira C., Nguyen V.H., Wijeysundera H., Wong, W. W. L., Woo, G., Liu P., Krahn M. (2012). How Much Are We Really Spending? The Estimation of the Expenditures on Cardiovascular Disease Research in Canada.  BMC Health Services Research, v12:281. [Link]
 
  • Wong W. W. L., Woo, G., Heathcote J.E., Krahn M. (2011). Cost Effectiveness of Screening Immigrants to Canada for Hepatitis B.  Liver international, v31, 8:1179-1190 [Link]
 
  • Wong W. W. L. and Burkowski F. J. (2011).  Using Kernel Alignment to Select Features of Molecular Descriptors in a QSAR study, IEEE Transactions on Computational Biology and Bioinformatics, v8, 5:1373-1384. [Link]
 
  • Feng Z., Wong W. W. L., Gao X., Schenkel F. (2011) Generalized Genetic Association Study with Samples from Related Populations, Annals of applied statistics, v5, 3:2109-2130. [Link]
 
  • Wong W. W. L. and Burkowski F. J. (2009).  A Constructive Approach for Discovering New Drug Leads: Using a Kernel Methodology for the Inverse-QSAR Problem, Journal of ChemInformatics, v1:4 [Link]
 
  • Wong W. W. L. and Burkowski F. J. (2009).  Predicting Multiple Binding Modes Using a Kernel Method Based on a Vector Space Model Molecular Descriptor, International Journal of Computational Biology and Drug Design, v2, 1:58–80. [Link]